Wrapping up 2025: A tumultuous year for global public health law & policy
The end of 2025, a tumultuous year for global public health, is here, and it’s time for the usually highly biased Medicines Law &...
Will the European Court of Justice put a stop to the evergreening of Truvada...
Truvada, the fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is a critical medicine in both HIV treatment and prevention. It is...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
Dutch health insurance company Menzis takes AstraZeneca to court over patent evergreening
Today health insurance company Menzis announced that it is taking the pharmaceutical company AstraZeneca to court over the pricing of Seroquel, a medicine...
The elephant in the room at the WHO Executive Board
The World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus spoke harshly about the lack of Covid-19 vaccines in developing countries at the opening of...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
The new IP strategy of war-torn Ukraine should prioritise public health and national security
Russia’s full-scale assault on Ukraine continues for the third year. The Russian occupation forces have already killed tens of thousands of civilians, including children. They have...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
Will Europe block the Pandemic Agreement because of one word?
This commentary originally appeared in the Brussels Times, and is available here.
The Pandemic Agreement negotiations began in December of 2021. Sufficiently motivated by the...
European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...
On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...